| Israel | Türkei | Österreich | |
| Chemotherapie bei Brustkrebs | von $22,500 | von $1,200 | von $15,000 |
| Strahlentherapie bei Darmkrebs | - | von $7,000 | von $12,000 |
Dr. Pelles Sharon spezialisiert sich auf fortschrittliche Behandlungen von Leberkrebs am Sourasky Medical Center, einschließlich Leberresektion und Chemoembolisation.
Prof. Merimsky leitet die Abteilung für Weichteil- und Knochenonkologie am Sourasky Medical Center und ist auf komplexe Krebsfälle spezialisiert.
Prof. Nadir Arber leitet das Integrierte Krebspräventionszentrum am Sourasky Medical Center in Israel und ist auf gastrointestinale Onkologie spezialisiert.
Dr. Arnon Nagler ist ein international anerkannter Hämatologe und Experte für Knochenmarktransplantationen. Er ist Professor für Medizin an der Universität Tel Aviv. Am Sheba Medical Center ist er emeritierter Direktor der Hämatologie & Knochenmarktransplantation sowie der Nabelschnurblutbank. Er erwarb seinen M.D. an der Hebrew University–Hadassah und einen M.Sc. in Hämatopoese an der Universität Tel Aviv. Seine Postdoc-Ausbildung absolvierte er an der Stanford University. Er ist fachärztlich in Innerer Medizin und Hämatologie anerkannt.
Er verfügt über mehr als 35 Jahre Erfahrung. Er war Pionier allogener Transplantationsprotokolle mit reduzierter Intensität für maligne und nichtmaligne Erkrankungen. Er gründete Israels erste öffentliche Nabelschnurblutbank und führte die ersten Nabelschnurbluttransplantationen des Landes durch.
Er hatte internationale Führungsrollen inne: Vorsitzender und Co‑Vorsitzender der ALWP der EBMT, stellvertretender Vorsitzender und langjähriges Mitglied von EBMT‑Gremien. Er gehörte dem Vorstand von NetCord/EuroCord an und war deren Schatzmeister. Er ist ein gefragter Referent, hat in Fachzeitschriften wie Blood und Leukemia umfangreich publiziert, leitete als Principal Investigator große klinische Studien und übernahm redaktionelle Funktionen. Für Innovation und klinische Exzellenz erhielt er zahlreiche Auszeichnungen.
Stage 3 liver cancer is treatable with surgery in Israel if the tumor is resectable and liver function remains stable. Specialists use advanced procedures like partial hepatectomy or ex-vivo resection. Eligibility depends on vascular involvement and the absence of distant metastasis.
Bookimed Expert Insight: Data shows that choosing high-volume centers like Sheba or Sourasky is vital for complex stages. These facilities perform over 34,000 to 45,000 operations annually. This high frequency allows surgeons to maintain expertise in rare procedures like ex-vivo resection. Patients benefit from multidisciplinary teams that often re-evaluate cases initially labeled as inoperable elsewhere.
Patient Consensus: Patients note that a second opinion is essential because assessments of operability vary between surgeons. They emphasize asking exactly why surgery is not recommended to explore downstaging options.
Israeli hospitals provide advanced non-surgical local therapies including transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), and microwave ablation. These minimally invasive procedures target stage 3 tumors when surgery is not possible. Specialized JCI-accredited centers use these techniques to halt progression.
Bookimed Expert Insight: Data shows Israeli specialists like Dr. Pelles Sharon at Sourasky Medical Center often combine SIRT with immunotherapy. This dual approach is common in high-volume clinics like Sheba, which treats over 1,900,000 patients annually. While ablation is standard for small nodules, Israeli oncologists frequently use microwave ablation for larger stage 3 masses. This is possible due to the high density of robotic and digital imaging technologies at these academic centers.
Patient Consensus: Patients note that TACE is a common bridge therapy to slow tumor growth. Many emphasize that doctors prioritize liver function scores over tumor stage when choosing between radiation and embolization.
Advanced and experimental therapies are widely available in Israel for inoperable cancer. Patients access cutting-edge protocols through international clinical trials and compassionate use programs. Leading academic centers specialize in cellular immunotherapies, precise radioactive micro-technologies, and molecularly targeted biological regimens for unresectable tumors.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Sourasky (Ichilov) often successfully downstage tumors once labeled inoperable. Prof. Dr. Almog Ben Yaacov at Sheba, for instance, uses microwave liver ablation and robot-assisted technology to treat complex cases. A high volume of clinical trials and 90% oncology success rates at Ichilov indicate that multidisciplinary reviews frequently find new surgical or systemic pathways.
Patient Consensus: Patients emphasize the value of a multidisciplinary tumor board review. Inoperable status can change after evaluation by a hepatobiliary surgeon and an interventional radiologist together.
Israeli medical centers like Sheba and Sourasky lead in treating Stage 3 liver cancer through multidisciplinary tumor boards. These JCI-accredited facilities provide advanced therapies including SIRT radioembolization and complex hepatectomy. High survival rates are achieved using integrated surgical oncology and personalized immunotherapy protocols.
Bookimed Expert Insight: Israeli oncology centers demonstrate high expertise through specialized leadership roles. Dr. Yuri Goldes at Sheba pioneered the first robotic oncologic resections in Israel. This technical depth allows for minimally invasive approaches even in complex Stage 3 cases. Patients benefit from surgeons who perform over 200 specialized procedures like HIPEC annually.
Patient Consensus: Patients emphasize that top-tier results come from hospitals using full liver tumor boards. They recommend getting second opinions from major academic centers to confirm the best treatment combination.
International patients can begin liver cancer treatment in Israel within 3 to 5 days of arrival. Evaluation starts immediately after online medical file review. If diagnostic scans are current, specialists can confirm a treatment plan within 48 to 72 hours of the first consultation.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Sourasky prioritize multidisciplinary tumor board reviews for stage 3 cases. This ensures that surgeons, hepatologists, and interventional radiologists evaluate resectability together. Choosing a center with specialized hepatobiliary units typically shortens the path from initial scan to the first procedure by at least 48 hours.
Patient Consensus: Patients note that arriving with complete pathology reports and recent PET-CT scans avoids redundant testing delays. They emphasize that while consultations happen quickly, the real key to speed is having a dedicated coordinator handle medical translations before landing.